In short
Clinical trials investigating Vemircopan are studying whether it can help people with kidney diseases such as lupus nephritis and IgA nephropathy. These trials mainly look at efficacy and safety in adults with these conditions, using measures like protein in the urine.
Key points
- Clinical trial data for Vemircopan show one completed Phase 2 study in people with proliferative lupus nephritis or IgA nephropathy. The study compared Vemircopan with placebo tablets in 126 participants. The main goal was to see the percentage change in proteinuria, or protein in the urine. This means the trial focused on whether the treatment could improve kidney disease signs. The available data centers on kidney conditions rather than other diseases.
Trial overview
The available clinical trial data for Vemircopan includes one study, NCT05097989, which was a completed Phase 2 interventional trial. The study tested ALXN2050 and compared it with placebo tablets in people with kidney disease.
Conditions studied
This trial studied lupus nephritis and IgA nephropathy, which are both kidney diseases. Lupus nephritis means kidney inflammation linked to lupus, while IgA nephropathy is a disease where IgA builds up in the kidneys and can lead to damage.
The title of the study also described lupus nephritis as proliferative, which means a more active or severe form of the disease.
Who could participate
The study enrolled participants with proliferative lupus nephritis or IgA nephropathy. The source data do not provide extra details about age limits, sex, kidney function limits, or other entry rules.
Study design and phase
This was a Phase 2 study, which is a mid-stage trial that usually checks whether a treatment may work and continues to monitor safety. It was an interventional study, meaning researchers gave a study treatment and compared it with a control treatment.
The study used ALXN2050 tablets and placebo tablets, so participants were compared against a treatment that looked the same but did not contain the active study drug.
Outcomes measured
The main outcome was the percentage change in proteinuria. Proteinuria means too much protein in the urine, which can be a sign that the kidneys are not filtering blood normally.
The brief summary says the trial aimed to evaluate the efficacy of ALXN2050 to reduce proteinuria in participants with lupus nephritis or IgA nephropathy. In simple terms, the study asked whether the treatment could lower the amount of protein leaking into the urine.